JP2014530841A - Ｄｇｌａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法 - Google Patents

Ｄｇｌａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法 Download PDF

Info

Publication number
JP2014530841A
JP2014530841A JP2014536268A JP2014536268A JP2014530841A JP 2014530841 A JP2014530841 A JP 2014530841A JP 2014536268 A JP2014536268 A JP 2014536268A JP 2014536268 A JP2014536268 A JP 2014536268A JP 2014530841 A JP2014530841 A JP 2014530841A
Authority
JP
Japan
Prior art keywords
weight
dgla
composition
hetre
composition comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014536268A
Other languages
English (en)
Japanese (ja)
Inventor
クリマックス ジョン
クリマックス ジョン
コウグフラン デビッド
コウグフラン デビッド
マンク メハル
マンク メハル
Original Assignee
ディグニティサイエンシスリミテッド
ディグニティ サイエンシス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディグニティサイエンシスリミテッド, ディグニティ サイエンシス リミテッド filed Critical ディグニティサイエンシスリミテッド
Publication of JP2014530841A publication Critical patent/JP2014530841A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014536268A 2011-10-19 2012-10-19 Ｄｇｌａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法 Pending JP2014530841A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549022P 2011-10-19 2011-10-19
US61/549,022 2011-10-19

Publications (1)

Publication Number Publication Date
JP2014530841A true JP2014530841A (ja) 2014-11-20

Family

ID=47071272

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014536268A Pending JP2014530841A (ja) 2011-10-19 2012-10-19 Ｄｇｌａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法

Country Status (15)

Country Link
US (1) US8936803B2 (pt)
EP (1) EP2768496A1 (pt)
JP (1) JP2014530841A (pt)
KR (1) KR20140091690A (pt)
CN (1) CN104010637A (pt)
AU (1) AU2012324853A1 (pt)
BR (1) BR112014009822A2 (pt)
CA (1) CA2852368A1 (pt)
IL (1) IL232115A0 (pt)
MX (1) MX2014004710A (pt)
PH (1) PH12014500859A1 (pt)
RU (1) RU2014119948A (pt)
SG (1) SG11201401629XA (pt)
WO (1) WO2013057287A1 (pt)
ZA (1) ZA201402820B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US10017453B2 (en) * 2013-11-15 2018-07-10 Ds Biopharma Limited Pharmaceutically acceptable salts of fatty acids
KR102391827B1 (ko) 2014-06-04 2022-04-27 디에스 바이오파마 리미티드 Dgla를 포함하는 약제학적 조성물 및 그의 용도
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
ES2851525T3 (es) 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
AU2016370626B2 (en) 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194446A1 (en) * 2002-04-10 2003-10-16 Akes Lindy K. Zinc oxide compositions for dermatheraputics
JP5546087B2 (ja) * 2005-02-14 2014-07-09 サントリーホールディングス株式会社 皮膚疾患経口治療または予防剤
CA2599112C (en) * 2005-02-14 2013-10-22 Suntory Limited Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient
GB0907413D0 (en) * 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof

Also Published As

Publication number Publication date
CA2852368A1 (en) 2013-04-25
KR20140091690A (ko) 2014-07-22
PH12014500859A1 (en) 2014-10-20
BR112014009822A2 (pt) 2017-06-13
SG11201401629XA (en) 2014-05-29
ZA201402820B (en) 2015-11-25
RU2014119948A (ru) 2015-11-27
WO2013057287A1 (en) 2013-04-25
MX2014004710A (es) 2014-12-10
US20130101533A1 (en) 2013-04-25
IL232115A0 (en) 2014-05-28
AU2012324853A1 (en) 2014-05-01
CN104010637A (zh) 2014-08-27
EP2768496A1 (en) 2014-08-27
US8936803B2 (en) 2015-01-20

Similar Documents

Publication Publication Date Title
JP2014530841A (ja) Ｄｇｌａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法
JP7416849B2 (ja) ｍＴＯＲ阻害剤の無水組成物およびその使用方法
Chiu et al. Epigallocatechin gallate/L-ascorbic acid–loaded poly-γ-glutamate microneedles with antioxidant, anti-inflammatory, and immunomodulatory effects for the treatment of atopic dermatitis
EP2174648B1 (en) Skin-care compositions and uses thereof
US6645510B1 (en) Method of treating topical ailments
JP2017226664A (ja) Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法
MX2011004040A (es) Composiciones de nsaid topicas que tienen componentes percibidos por los sentidos.
US20090137534A1 (en) Skin treatment compositions and methods
US20030104018A1 (en) Skin product having micro-spheres, and processes for the production thereof
KR101892079B1 (ko) 여드름 개선용 조성물 및 이를 포함하는 여드름 개선용 키트
RU2475230C1 (ru) Лечебно-косметическое средство для защиты кожи от солнечных ожогов
US9855236B2 (en) Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
TR201911262T4 (tr) Melatonin veya bunun türevleri ile koenzim q10 içeren bileşim ve bunun cilt yaşlanmasına karşı kullanımı.
RU2702347C2 (ru) Лечение или профилактика себорейного кератоза с применением артемизинина и его производных
TW201632182A (zh) 治療皮膚之腫瘤及癌前病理的雷公藤內酯及其衍生物
JP2007230976A (ja) 顆粒球・マクロファージコロニー刺激因子（ｇｍ−ｃｓｆ）産生抑制剤ｉ
US12064461B2 (en) Deep penetrating topical cannabinoid compositions and methods for treating musculoskeletal inflammation and pain
US12059393B2 (en) Compositions for topical treatment of radiation dermatitis
US11517578B1 (en) Topical formulations containing erythritol and methods of treating skin conditions
US8278289B2 (en) Boroxine composition for removal of skin changes
Blume Frankincense, an" Old Fashioned" Active Ingredient.
WO2023154264A1 (en) Compositions for topical treatment of radiation dermatitis
KR101774859B1 (ko) 인도시아닌 그린-함유 조성물의 광민감제 및 이를 포함하는 조성물
US20230115401A1 (en) Antimicrobial coating containing erythritol
KR20170088805A (ko) 인도시아닌 그린-함유 조성물의 광민감제 및 이를 포함하는 조성물